Skip to main content
MedPathMedPath Home
Clinical Trials/NCT03392181
NCT03392181
Active, Not Recruiting
Early Phase 1

PET/MRI for the Staging of Newly Diagnosed Prostate Cancer

Northwestern University1 site in 1 country48 target enrollmentJune 8, 2018
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsProstate Cancer
Interventions18F-DCFPyL
Drugs18F-DCFPyL

Overview

Phase
Early Phase 1
Intervention
18F-DCFPyL
Conditions
Prostate Cancer
Sponsor
Northwestern University
Enrollment
48
Locations
1
Primary Endpoint
PET/MR versus mp-MRI for the Staging of Newly Diagnosed Prostate Cancer
Status
Active, Not Recruiting
Last Updated
11 months ago
OverviewInvestigatorsEligibility CriteriaArms & InterventionsOutcomesSitesSimilar Trials

Overview

Brief Summary

The purpose of this study is to gain understanding of how PET-MR (positron emission tomography-magnetic resonance imaging) using the substance 18F-DCFPyL (PyL) may help in diagnosing prostate cancer and in determining the stage of prostate cancer before surgery.

Registry
clinicaltrials.gov
Start Date
June 8, 2018
End Date
June 1, 2026
Last Updated
11 months ago
Study Type
Interventional
Study Design
Single Group
Sex
Male

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Edward Schaeffer

Chair, Department of Urology, Program of Director for GU Oncology

Northwestern University

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

18F-DCFPyL

Intervention: 18F-DCFPyL

Outcomes

Primary Outcomes

PET/MR versus mp-MRI for the Staging of Newly Diagnosed Prostate Cancer

Time Frame: 5 years

To determine if PSMA-Targeted PET/MRI improves pre-operative staging of prostate cancer prior to radical prostatectomy compared to MRI alone.

Study Sites (1)

Loading locations...

Similar Trials

Recruiting
Early Phase 1
18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: A Pilot StudyProstate Cancer
NCT05707182University of Alabama at Birmingham30
Completed
Phase 1
A Study of PET/CT Imaging Using INR101 Injection in Healthy Male Subjects and Patients With Suspected Prostate CancerHealthy Male SubjectsSuspected Prostate Cancer
NCT06472531Yunhe Pharmaceutical (Tianjin) Co., Ltd32
Unknown
Phase 1
PET-CT/MRI in the Radiotherapy for Prostate CancerProstate Cancer
NCT02816840Xuzhou Medical University90
Active, Not Recruiting
Phase 2
Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer OutcomesProstate Adenocarcinoma
NCT03762759Emory University140
Recruiting
N/A
Diagnostic Performance of PET Imaging for Prostate Specific Membrane Antigen (PSMA)Prostate cancer
JPRN-UMIN000037697Osaka University Graduate School of Medicine250